Ulipristal Use in Chinese Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-02

Study Completion Date

2020-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Uterine leiomyomas is the commonest benign tumour of the female genital tract. It lead to menorrhagia, anaemia, pain and pressure symptoms. Due to the enlarged uterus, the use of minimal invasive surgery is limited. There is also increase risk of intraoperative blood transfusion. Ulipristal acetate (UPA) is a selective progesterone-receptor modulator (SPRM). Preoperative use of Ulipristal for 12 weeks has been shown to decrease uterine bleeding, fibroid volume, pre-operative anaemia and symptoms severity. However there is still lacking evidence in terms of long term safety and efficacy, especially in Chinese population. The aim of the present study is to evaluate the effect and safety on preoperative use of Ulipristal on fibroid.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma

NCT02361879

Fibroid

UNKNOWN PHASE4

Ulipristal vs. GnRHa Prior to Laparoscopic Myomectomy

NCT02288130

Fibroids

UNKNOWN PHASE4

Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)

NCT04004884

Leiomyoma, Uterine Liver Injury Treatment Side Effects

TERMINATED

Microwave Ablation for Uterine Fibroids

NCT04073485

Uterine Fibroid

TERMINATED NA

PREOPERATIVE GONADOTROPINE-RELEASING HORMONE AGONIST THERAPY BEFORE SURGERY FOR UTERİN FIBROIDS

NCT04192812

Uterine Fibroid Gonadotropin-Releasing Hormone-Dependent Precocious Puberty

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Uterine leiomyomas is the commonest benign tumour of the female genital tract. It is often asymptomatic, but can also lead to anaemia, pain and pressure symptoms. It is the commonest indication for hysterectomy, especially abdominal hysterectomy. Currently, the use of hormonal treatment is associated with side effects including gastrointestinal upset, bloating, weight gain and thromboembolic risks. The main stay for treatment relies on surgery.

Furthermore, the use of minimal invasive surgeries is limited by the size of the fibroids. Preoperative use of Gonadotrophic Releasing Hormone analogues (GnRHa) is effective in shrinkage of the uterine leiomyomas and reduction of uterine bleeding. However, postmenopausal symptoms including hot flushes, vaginal dryness are profound.

Ulipristal acetate (UPA), previously named CDB-2914, is a selective progesterone-receptor modulator (SPRM). It binds to the progesterone receptors with high affinity. It inhibits follicular development and ovulation, while it has no significant effects on estradiol levels and antiglucocorticoid activity. Preoperative use of Ulipristal for symptomatic uterine fibroids has been investigated in randomized controlled study with improvement in terms of uterine bleeding, fibroids volume, pre-operative anaemia and symptoms severity. However there is still lacking evidence in terms of long term safety and efficacy. Also there is lack of evidence in Chinese population.

The aim of the present study is to evaluate the effect and safety on preoperative use of Ulipristal on fibroid.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fibroid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ulipristal

Patients will be prescribed Ulipristal acetate 5mg daily for 12 weeks before operation. If the patients have anaemia with haemoglobin less than 10g/dL, ferrous sulphate 300mg three times a day will be prescribed as well. Tranexamic Acid 500mg four times a day will be prescribed on request basis.

Group Type EXPERIMENTAL

Ulipristal acetate

Intervention Type DRUG

Ulipristal acetate 5mg daily will be prescribed

Ferrous sulphate

Intervention Type DRUG

Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.

Tranexamic Acid

Intervention Type DRUG

Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.

Placebo

Patients will be prescribed placebo pills daily for 12 weeks before operation. If the patients have anaemia with haemoglobin less than 10g/dL, ferrous sulphate 300mg three times a day will be prescribed as well. Tranexamic Acid 500mg four times a day will be prescribed on request basis.

Group Type PLACEBO_COMPARATOR

Placebo pills

Intervention Type OTHER

Placebo pills will be prescribed

Ferrous sulphate

Intervention Type DRUG

Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.

Tranexamic Acid

Intervention Type DRUG

Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ulipristal acetate

Ulipristal acetate 5mg daily will be prescribed

Intervention Type DRUG

Placebo pills

Placebo pills will be prescribed

Intervention Type OTHER

Ferrous sulphate

Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.

Intervention Type DRUG

Tranexamic Acid

Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Esyma Ferasul Transamin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Scheduled for hysterectomy for symptomatic fibroid
* Be a Chinese
* Pre-menopausal
* With a Pictorial bleeding assessment chart score \> 100 during menstruation at the preceding month
* Non-pregnant
* With a body-mass index between 18 to 30.

Exclusion Criteria

* History of uterine surgery (apart from Caesarean section or cervical conization), endometrial ablation or uterine artery embolization
* History of gynaecological malignancies
* History of endometrial hyperplasia
* Known haemoglobinopathy (e.g. thalassaemia)
* Known severe coagulation disorder
* Has one or more ovarian cysts \>= 4 cm in diameter diagnosed by ultrasound
* History of use of Selective Progesterone Receptor Modulator (SPRM)
* Current (within 12 months) problem with alcohol or drug abuse.
* Known allergy to SPRM or ferrous sulphate

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No